Home › NDC Lookup › RxCUI directory › RxCUI 977840

3 ML insulin aspart protamine, human 70 UNT/ML / insulin aspart, human 30 UNT/ML Pen Injec... — RxCUI 977840

RxNorm drug concept · Semantic branded drug
RxCUI 977840 Semantic branded drug · SBD ● Current RxNorm concept 6 FDA products 6 package NDCs Snapshot Jul 14, 2026

This page is curated, coded, and maintained by

Compiled from public NLM RxNorm and FDA (openFDA NDC directory) data sources. Editorial policy

What you’re looking at: the standardized identity of one medicine, as the U.S. drug-data system sees it. Below — every FDA-listed product, package code, price benchmark, and billing code that maps to it.

🗂️ Key Facts

RxCUI977840
Official name3 ML insulin aspart protamine, human 70 UNT/ML / insulin aspart, human 30 UNT/ML Pen Injector [NovoLog Mix]
Concept typeSemantic branded drug (SBD)
RxNorm statusCurrent RxNorm concept
Also known asNovoLog Mix 70/30 per 3 ML Pen Injector; NovoLOG Mix 70/30 in 3 ML Pen Injector
FDA products mapped6
Package NDCs mapped6
Reported Medicaid activity (SDUD)15,489 prescriptions · 40 state & territory Medicaid programs · latest period Q4 2025
RxNorm release07/06/2026
Snapshot dataJul 14, 2026

📖 Skip the Codes — Read It in Plain English.

Our pharmacist-built guide to Insulin Aspart (rDNA Origin) Injection: what it is, how it’s used, side effects, and interactions.

📗 Our plain-language guide HelloPharmacist
  • Insulin aspart is a man-made, rapid-acting insulin that is very similar to the insulin your body makes naturally, but it works faster. After you inject it under the skin, it starts...
  • What exactly is insulin aspart and how is it different from regular insulin?
  • Generally, you should inject it within about 5 to 10 minutes before a meal so it starts working as your blood sugar begins to rise from food. The exact timing depends on which prod...
  • When should I inject insulin aspart — before or after eating?
📖 Read our full Insulin Aspart (rDNA Origin) Injection guide →

🕸️ Concept Web — How 3 ML insulin aspart protamine, human 70 UNT/ML /... Connects

One RxCUI never lives alone. Follow the path from the raw ingredient down to the exact strength-and-form concepts FDA products carry — every stop is a real RxNorm concept with its own identifier. Hover or focus any chip for what it means.
This page's concept 3 ML insulin aspart protamine, human 70 UNT/ML / insulin aspart, human 30 UNT/ML Pen Injector [NovoLog Mix] RxCUI 977840

Every web starts here: one RxCUI, one fixed meaning in the RxNorm vocabulary.

  1. Ingredients 3

    The active substance itself — no strength, form, or brand attached yet.

    • Insulin aspart protamine, human 352385
    • Insulin aspart, human 51428
    • Insulin aspart protamine, human / insulin aspart, human 1007184
  2. Brand names 1

    The same medicine's trade names. A brand name alone says nothing about strength or form.

    • NovoLog Mix 1372741
  3. Dose forms 6

    The ingredient poured into a form — tablet, solution, cream — still without one fixed strength.

    • Insulin aspart protamine, human / insulin aspart, human Pen Injector 1653207
    • Insulin aspart protamine, human / insulin aspart, human Injectable Product 1157462
    • Insulin aspart protamine, human / insulin aspart, human Pen Injector [NovoLog Mix] 1653209
    • NovoLog Mix Injectable Product 1178120
    • Pen Injector 1649571
    • Injectable Product 1151126
  4. Clinical & branded drugs 4

    Ingredient + strength + dose form. These are the concepts real FDA products actually carry.

Showing up to 8 concepts per family — 14 of 14 stored related concepts drawn.
These are official RxNorm vocabulary relationships — how concepts name and organize the same medicine. They do not establish therapeutic equivalence or substitutability: two concepts appearing in one web is never a statement that products can be swapped.

🔀 Generic ⇄ Brand Crosswalk

The same medicine has an unbranded (generic) identity and one or more brand-name identities — each with its own RxCUI. This is a naming relationship in RxNorm, not a statement that any two products are substitutable.

Generic (Clinical) Concepts

Brand-Name Concepts

  • Insulin aspart protamine, human 70 UNT/ML / insulin aspart, human 30 UNT/ML [NovoLog Mix] SBDC · 977838
  • Insulin aspart protamine, human / insulin aspart, human Pen Injector [NovoLog Mix] SBDF · 1653209
  • NovoLog Mix Injectable Product SBDG · 1178120
  • NovoLog Mix BN · 1372741

📦 FDA Products & Package NDCs

6 products · 6 package NDCs
6 package NDCs map to RxCUI 977840 in the current snapshot — up to 50 per page. Each linked NDC opens its full package page.
Package NDC Package Brand / generic name Labeler Marketing start
00169-2200-11 1 VIAL, GLASS in 1 CARTON (0169-2200-11) / 10 mL in 1 VIAL,... NovoLog Mix 70/30 Novo Nordisk 2021-07-01
00169-2201-25 5 SYRINGE, PLASTIC in 1 CARTON (0169-2201-25) / 3 mL in 1 S... NovoLog Mix 70/30 Novo Nordisk 2021-07-01
00169-3685-12 1 VIAL, GLASS in 1 CARTON (0169-3685-12) / 10 mL in 1 VIAL,... NovoLog Mix 70/30 Novo Nordisk 2001-11-01
00169-3696-19 5 SYRINGE, PLASTIC in 1 CARTON (0169-3696-19) / 3 mL in 1 S... NovoLog Mix 70/30 Novo Nordisk 2002-09-11
50090-2272-00 5 SYRINGE, PLASTIC in 1 CARTON (50090-2272-0) / 3 mL in 1 S... NovoLog Mix 70/30 A-S Medication Solutions 2015-12-15
70518-2119-00 5 SYRINGE, PLASTIC in 1 CARTON (70518-2119-0) / 3 mL in 1 S... NovoLog Mix 70/30 REMEDYREPACK INC. 2019-05-28
Observed labelers: Novo Nordisk (4) · A-S Medication Solutions (1) · REMEDYREPACK INC. (1) — this is the FDA-listed mapping footprint, not sales, inventory, availability, or market share.

💲 Pricing (NADAC)

NADAC is CMS's National Average Drug Acquisition Cost — roughly what pharmacies pay to buy the drug. It is an acquisition benchmark, not your copay.
Per ml · median
$7.9371
Range $6.9314–$8.9428 · middle 50% $7.4342–$8.4399 · 2 NDCs
Latest compatible distributions from the CMS NADAC file · dataset watermark 2026-07-10. Prices vary by package and pharmacy; a distribution is shown instead of one misleading number. Rows the dataset is silent on carry no price. No zero-cost conclusion should be drawn.

🗃️ Sources & Limits

Atlas generation902fddb9-e9c1-4004-bf4c-dba4d51037c7
openFDA export observedJul 14, 2026
RxNorm release07/06/2026
Methodology2026-07-full-catalog-v1
  • A shared RxCUI does not prove interchangeability. Products mapped to the same concept are not thereby equivalent or substitutable — equivalence is a separate, product-level determination.
  • Listing here does not establish approval or coverage. Appearing in this snapshot is a data observation, not an FDA approval status or a payer coverage decision.
  • Missing data never means zero. A silent dataset (no price, no billing code, no utilization) means no observation — not that the real-world value is zero.
  • Counts describe the mapping footprint. Product, package, and labeler counts are the FDA-listed mapping footprint in this snapshot — not sales, inventory, availability, or market share.
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.

Machine-readable JSON

Reference information about drug-concept identifiers and public regulatory data — not medical advice. Talk to your pharmacist or prescriber about your own medication.